Literature DB >> 4027460

Effects on rabbit cardiac potentials of aprindine and indecainide, a new antiarrhythmic agent, in normoxia and hypoxia.

P D Dennis, E M Vaughan Williams.   

Abstract

Intracellular potentials were recorded from rabbit atria, cardiac Purkinje cells and papillary muscles before and after exposure to various concentrations of indecainide. The effects of aprindine also were studied in the atrial preparations. Both drugs depressed the maximum rate of depolarization (MRD) in a dose-related manner, indecainide being approximately ten times more potent than aprindine. Aprindine caused a dose-related bradycardia, but indecainide had no significant effect on sinus node frequency. Indecainide had a dose-related negatively inotropic effect in normal, half-normal and twice-normal extracellular calcium concentrations. Indecainide shortened action potential duration (APD) in atrium and Purkinje cells but prolonged APD to 50% repolarization in ventricular muscle. The actions of indecainide were extremely persistent. No significant recovery of MRD was observed after pauses in stimulation of up to 16 s. Indecainide had no effect on effective refractory period (ERP) measured by interpolated premature stimuli. Indecainide is therefore categorized as a Class 1c antiarrhythmic agent. The effects of both aprindine and indecainide on MRD were increased in hypoxic atria. Conduction velocity in hypoxic atria exposed to indecainide was greater than in controls, however, suggesting the possibility of improved cell-to-cell coupling.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027460      PMCID: PMC1916771          DOI: 10.1111/j.1476-5381.1985.tb08825.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  Investigations to characterize a new anti-arrhythmic drug, ORG 6001 including a simple test for calcium antagonism.

Authors:  L A Salako; V Williams; J H Wittig
Journal:  Br J Pharmacol       Date:  1976-06       Impact factor: 8.739

2.  Intracellular electrophysiological alterations in canine cardiac conducting tissue induced by aprindine and lignocaine.

Authors:  M I Steinberg; K Greenspan
Journal:  Cardiovasc Res       Date:  1976-03       Impact factor: 10.787

3.  Effects of aprindine and lidocaine on transmembrane potentials and radioactive K efflux in different cardiac tissues.

Authors:  E Carmeliet; F Verdonck
Journal:  Acta Cardiol       Date:  1974       Impact factor: 1.718

4.  The multiple modes of action of propafenone.

Authors:  I D Dukes; E M Vaughan Williams
Journal:  Eur Heart J       Date:  1984-02       Impact factor: 29.983

5.  Agranulocytosis and aprindine.

Authors:  R van Leeuwen; R H Meyboom
Journal:  Lancet       Date:  1976-11-20       Impact factor: 79.321

6.  Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide.

Authors:  T J Campbell; E M Vaughan Williams
Journal:  Cardiovasc Res       Date:  1983-05       Impact factor: 10.787

7.  Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia.

Authors:  J S Millar; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1982-03       Impact factor: 8.739

8.  The relevance of beta-receptor blockade to ouabain-induced cardiac arrhythmias.

Authors:  A N Dohadwalla; A S Freedberg; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1969-06       Impact factor: 8.739

9.  Resting and rate-dependent depression of maximum rate of depolarisation (Vmax) in guinea pig ventricular action potentials by mexiletine, disopyramide, and encainide.

Authors:  T J Campbell
Journal:  J Cardiovasc Pharmacol       Date:  1983 Mar-Apr       Impact factor: 3.105

10.  Electrophysiological studies of indecainide hydrochloride, a new antiarrhythmic agent, in canine cardiac tissues.

Authors:  M I Steinberg; S A Wiest
Journal:  J Cardiovasc Pharmacol       Date:  1984 Jul-Aug       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.